2022
Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials
Sprangers B, Perazella MA, Lichtman SM, Rosner MH, Jhaveri KD. Improving Cancer Care for Patients With CKD: The Need for Changes in Clinical Trials. Kidney International Reports 2022, 7: 1939-1950. PMID: 36090489, PMCID: PMC9458993, DOI: 10.1016/j.ekir.2022.06.005.Peer-Reviewed Original ResearchChronic kidney diseaseEnd-stage kidney diseaseSevere kidney dysfunctionKidney diseaseKidney dysfunctionAdvanced kidney diseaseOptimal clinical careCancer drug trialsNumber of patientsNarrow therapeutic indexInitial clinical studiesKidney replacement treatmentPreregistration studiesKidney functionCancer careReplacement treatmentCancer trialsClinical trialsEffective dosingClinical studiesTreatment decisionsDrug trialsBeneficial drugsClinical carePatients
2004
Intravenous Iron and the Risk of Infection in End‐Stage Renal Disease Patients
Perazella M, Brewster U, Perazella M. Intravenous Iron and the Risk of Infection in End‐Stage Renal Disease Patients. Seminars In Dialysis 2004, 17: 57-60. PMID: 14717813, DOI: 10.1111/j.1525-139x.2004.17115.x.BooksConceptsInnate immune responseRisk of infectionIntravenous ironEnd-stage renal disease patientsHost innate immune responseRenal disease patientsIron-deficient patientsAdministration of ironOral ironIron therapyMost patientsHemodialysis patientsActive infectionDisease patientsIron preparationsIron overloadAllergic reactionsClinical studiesImmune responsePatientsBacterial infectionsIron deficiencyInfectionRiskBacterial growth
2001
NSAIDs and the Kidney Revisited: Are Selective Cyclooxygenase-2 Inhibitors Safe?
Eras J, Perazella M. NSAIDs and the Kidney Revisited: Are Selective Cyclooxygenase-2 Inhibitors Safe? The American Journal Of The Medical Sciences 2001, 321: 181-190. PMID: 11269794, DOI: 10.1097/00000441-200103000-00005.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsCOX-2 selective inhibitorsSelective cyclooxygenase-2 inhibitorRenal effectsCyclooxygenase-2 inhibitorNonselective nonsteroidal anti-inflammatory drugsSelective nonsteroidal anti-inflammatory drugsSelective COX-2 inhibitorsAdverse renal effectsBaseline patient characteristicsAdverse gastrointestinal effectsCOX-1/COXCyclooxygenase enzyme activityAnti-inflammatory drugsCOX-2 inhibitorsCOX-2 enzymePatient characteristicsGastrointestinal effectsChronic painGastric erosionsInflammatory conditionsClinical studiesClinical investigationKidney tissueKidney